R&D Knowledge Intelligence Factory
Highly Differentiated Offering — Where pipeline strategy leaks through the tools used to build it
The Problem in Numbers
Based on internal market research. Figures are directional estimates informed by industry analysis and may vary by organisation.
35M+
PubMed Abstracts in Corpus
$1M+
Annual Commercial AI API Spend
10K+
Patent Filings Per Week
6–12 mo
Competitive Signal Detection Lag
Why Cloud Fails for R&D Intelligence
Three problems that compound simultaneously — and none of them are solved by a better cloud contract:
IP Leakage
Every query sent to a commercial AI API reveals what the R&D team is investigating. Patent searches expose target priorities. Literature queries expose mechanisms. Competitive analysis queries expose the entire pipeline roadmap. Query patterns are data.
Budget-Gated Iteration
R&D cycles are throttled by cloud GPU cost-approval processes. Scientists wait weeks for infrastructure budget sign-off. A hypothesis that deserves an answer in hours waits weeks for finance approval. Cloud GPU billing punishes exactly this kind of sustained scientific workload.
Fragmented Governance
R&D, Computational Biology, Genomics, and Competitive Intelligence teams each run separate cloud AI contracts — 3–5 vendors per organisation, no shared audit trail, no cost reuse, no governance. Total R&D AI spend is invisible.
Intelligence Sources in Scope
Scientific literature
PubMed (35M+ abstracts), bioRxiv, medRxiv, EMBASE — continuously ingested, deduplicated, and versioned. Quarterly full-corpus re-analysis for comprehensive signal coverage.
Patent filings
USPTO, EPO, WIPO, J-PAT feeds — 10,000+ weekly filings normalised, entity-extracted, and scored for mechanism-of-action proximity to internal pipeline assets.
Conference abstracts
ASCO, ACS, AHA, ESMO, ASH, BIO — 50,000+ abstracts annually, structured into therapeutic area clusters with KOL attribution and trial linkage.
Internal compound databases
Proprietary assay results, hit libraries, ADMET profiles, and structure-activity data. Inference runs entirely on-prem — zero egress of compound IP to cloud providers.
Competitive pipeline databases
Citeline, GlobalData, and internal CI feeds normalised into a single queryable graph — competitor pipeline stage, target overlap, mechanism similarity scoring.
Clinical trial registries
ClinicalTrials.gov, EudraCT, ISRCTN — trial initiation signals, endpoint selection trends, and emerging indication patterns extracted in near-real-time.
Genomic datasets
Internal patient samples (WGS, WES), reference databases (gnomAD, ClinVar, 1000 Genomes). Inference on pre-trained genomic foundation models — fully on-prem, zero egress.
KOL publication streams
Tracked publication histories for 500–2,000 key opinion leaders per therapeutic area. New outputs trigger automated relevance scoring against internal pipeline interests.
The Solution
A four-stage inference platform purpose-built for corpus-scale R&D intelligence workloads
Corpus Ingestion
& Governance
& Governance
→
Knowledge
Twin
Twin
→
Hypothesis
Engine
Engine
→
Discovery
Copilot
Copilot
STAGE 1
Corpus Ingestion & Governance
Every abstract, patent filing, and dataset is fingerprinted and catalogued before AI processing begins. Source credentialing, deduplication, format normalisation, version management, and ingestion tracking form the file-level control plane for the knowledge corpus.
Source Credentialing
Deduplication
Version Management
Ingestion Tracking
STAGE 2
Knowledge Twin
Raw literature is transformed into a structured, queryable knowledge graph. Entity extraction (targets, mechanisms, genes, compounds), relationship mapping, citation graph construction, and mechanism-of-action scoring — with full lineage back to source documents.
Entity Extraction
Relationship Mapping
Citation Graphs
MoA Scoring
STAGE 3
Hypothesis Engine
Cross-corpus scientific reasoning at scale — mechanism-of-action similarity scoring, competitive pipeline gap analysis, novelty assessment against prior art, compound–target affinity inference, and patent white-space identification across therapeutic areas.
MoA Similarity
Pipeline Gap Analysis
Patent White-Space
Compound-Target Affinity
STAGE 4
Discovery Copilot
Scientist-facing interface with structured query submission, ranked literature evidence, competitive landscape signals, and patent white-space maps. No pipeline decision is committed without human review — human-in-the-loop by design, with every query immutably logged.
Ranked Evidence
Competitive Signals
Human-in-the-Loop
Audit-Logged Queries
The CPU preprocessing insight: Literature normalisation, patent parsing, entity pre-filtering, and genomic sequence alignment are entirely CPU-bound. Without right-sizing the CPU tier, the GPU inference tier sits idle waiting for preprocessed data. Intics solved this exact bottleneck at the Fortune 25 customer — the optimised CPU/GPU ratio is built into the platform, not learned on the customer's dime.
Proven Architecture
40–50B
Tokens / Day (Platform Capacity)
124 → 48
Pod Optimisation Journey
72B → 8B
Model Right-Sizing Evolution
The 5-Layer AI Cake
Who delivers what — tailored for corpus-scale R&D intelligence workloads
Layer 5: AGENCY (Discovery Copilot)
Scientist-facing query interface, human-in-the-loop review, immutable audit logging, prompt governance, namespace isolation per therapeutic area, multi-corpus pipeline orchestration
INTICS
Layer 4: INTELLIGENCE (Multi-Model Corpus Serving)
Silicon-aware placement (8B classification on Hopper, 72B deep analysis on H100), burst scheduling for quarterly corpus scans, genomic foundation model serving, vLLM / SGLang / Triton
INTICS
Layer 3: IRON (Servers, Networking & Storage)
UCS X/C-Series as GPU hosts, Nexus 9000 for high-bandwidth east-west traffic (terabyte-scale genomic data), MDS high-capacity storage for genomic data lakes and corpus snapshots, Intersight lifecycle management
CISCO
Layer 2: SILICON (Workload-Right-Sized)
Xeon / EPYC (128-core) for corpus preprocessing bottleneck, H100/A100 for deep analysis inference, NVIDIA Hopper for cost-optimised sustained NLP monitoring — silicon-agnostic, workload-driven selection
CISCO
Layer 1: ENERGY (Sustained Multi-Week Compute)
Multi-week R&D compute cycles require sustained high-density power. Cisco manages rack density, thermal design, redundant power feeds, UPS, and colocation partnerships for uninterrupted research cycles
CISCO
For R&D intelligence, the Cake has a unique storage dimension. Genomic data lakes, full-corpus snapshots, and proprietary compound libraries require high-capacity local storage — eliminating cloud egress fees and keeping IP inside the firewall permanently. Cisco's MDS storage is the on-prem replacement for the cloud storage bill.
Financial Impact
Dual savings stack — infrastructure replacement AND commercial API elimination on the same hardware
$240K
Cloud Inference / Month
$79K
Captive / Month
Mo 6–8
Break-Even (Faster Than Clinical Docs)
$5.5–9M
3-Year Net Savings
Lever 1 — Infrastructure
67%
Cost reduction vs. cloud GPU rental
$240K/mo → $79K/mo
$240K/mo → $79K/mo
Lever 2 — API Elimination
$1M+/yr
Commercial AI API spend eliminated
Elsevier, Clarivate, GPT-4 API replaced
Elsevier, Clarivate, GPT-4 API replaced
Cost Comparison
| Line Item | Cloud + Commercial APIs | Owned Infrastructure |
|---|---|---|
| Monthly inference cost | $180,000–$240,000 / mo | $72,000–$79,000 / mo |
| Commercial CI platform licences (Elsevier, Clarivate, Scite) | $600,000–$1,200,000 / yr | $0 (replaced by owned inference) |
| Cloud AI API (GPT-4 / Anthropic for R&D queries) | $200,000–$400,000 / yr | $0 (all queries on-prem) |
| One-time hardware Capex | $0 (rented) | $1,750,000 |
| Monthly operations (power, colo, ops, software, insurance) | Included in rental | $30,000 / mo |
| Data egress (genomic datasets, corpus snapshots) | $50,000–$100,000 / yr | $0 |
| GPU idle billing | Billed even when idle | Marginal electricity only |
Financial Outcomes
| Outcome | Value |
|---|---|
| Monthly savings (inference alone) | ~$161,000 / mo |
| Annual savings (incl. API + egress elimination) | ~$2.7M–$3.7M / yr |
| Break-even point | Month 6–8 (faster than Clinical Docs due to dual savings) |
| 3-year total (cloud + APIs + egress) | $10.4M–$15.2M |
| 3-year total captive spend | $2,844,000 + $1,750,000 Capex = $4,594,000 |
| 3-year net savings | ~$5,500,000–$9,000,000 |
| Hardware on balance sheet | $1,750,000 depreciable asset |
The dual-lever kicker: Unlike Clinical Document Processing, the R&D savings case has two independent financial drivers. The Capex pays for itself against infrastructure Opex alone in 6–8 months. The commercial API elimination — $600K–$1.2M/yr in licence fees replaced entirely — is pure additional savings on top. Both stacked on the same hardware investment.
Time Savings
From months to hours — across the R&D intelligence pipeline
6–12 mo → hrs
Competitive Signal Detection
72 hrs
Full PubMed Corpus Re-Analysis
~95%
Faster Patent White-Space Analysis
| Process | Before | After | Improvement |
|---|---|---|---|
| Competitive signal detection (new patent or competitor trial) | 6–12 months lag (batch analyst review) | Hours (continuous monitoring, automated alert) | Near-elimination of lag |
| Full PubMed corpus re-analysis (35M+ abstracts) | 3–6 months (manual triage + cloud batch) | 72 hours (burst: 40–50B tokens) | Months → 3 Days |
| Patent white-space analysis for a therapeutic area | 4–6 weeks (external consultant or manual) | 4–8 hours (automated corpus query) | ~95% reduction |
| Drug–target hypothesis validation against literature | Days to weeks (researcher manual search) | Minutes (Discovery Copilot query) | Orders of magnitude |
| R&D iteration cycle (genomics, compound screening) | Gated by cloud budget approval (2–4 weeks) | Gated only by scientific design | Infrastructure delay eliminated |
| KOL publication monitoring (500+ tracked authors) | Weekly manual scan or expensive API polling | Real-time ingestion + automated relevance scoring | Periodic → Continuous |
The most valuable time saving is not processing speed — it is the elimination of infrastructure-gated R&D cycles. When scientists own the inference platform, they stop rationing GPU time and start running experiments continuously. A hypothesis that would have waited 3 weeks for cloud budget approval gets answered in hours on owned infrastructure.
Volume & Throughput
Corpus-scale inference with CPU-optimised preprocessing and silicon-aware model placement
35M+
PubMed Abstracts (Full Corpus)
10K+
Patent Filings / Week Ingested
5–8B
Tokens / Day (Steady-State)
40–50B
Tokens / Day (Burst Capacity)
| Metric | Scale |
|---|---|
| PubMed corpus (full quarterly re-analysis) | 35M+ abstracts — processed in 72 hours at burst capacity |
| Weekly patent ingestion (normalised + scored) | 10,000+ filings across USPTO, EPO, WIPO, J-PAT |
| Token throughput (steady-state monitoring) | 5–8B tokens/day (continuous patent + literature monitoring) |
| Token throughput (burst — quarterly corpus scan) | 40–50B tokens/day for 72 hours |
| Concurrent inference pipelines | NLP entity extraction + citation graph + mechanism scoring + competitive gap analysis |
| Pod configuration (proven) | 48 H100 pods or 72 A100 pods |
| Model parameter range | 8B (triage/classification) → 72B (deep mechanism analysis) — right-sized per query type |
| Genomic data per patient (WGS) | 100–300 GB — CPU-intensive preprocessing, GPU inference on pre-trained models |
| CPU preprocessing (critical bottleneck) | Literature normalisation, patent parsing, entity pre-filtering — CPU-bound, not GPU-bound |
Burst vs. steady-state economics. R&D intelligence has a distinctive cost profile — steady-state continuous monitoring 90% of the time, with quarterly burst during PubMed corpus re-analysis cycles. Cloud charges 3× for burst capacity. The captive farm absorbs the quarterly burst at marginal electricity cost — because the hardware is already owned and powered. This is the identical economic argument as pharmacovigilance, but applied to R&D.
IP & Compliance
AI-assisted drug discovery faces a unique combination of IP exposure risk and regulatory defensibility requirements
Trade Secret Protection
Proprietary compound libraries, unpublished trial data, pipeline roadmap queries, and custom model weights represent billions in R&D investment. No legal or contractual framework adequately protects IP sent to a third-party cloud AI API. Captive inference eliminates the exposure category entirely — not just the risk.
Query Pattern Confidentiality
Every patent search reveals target priorities. Every literature query reveals mechanism focus. Every competitive analysis reveals pipeline strategy. Cloud AI providers aggregate query patterns as training data. Captive inference makes every R&D query invisible to everyone outside the company — the API call never leaves the firewall.
GDPR / Genetic Data Laws
Genomic data is the most sensitive data class in pharma. EU AI Act, GDPR Article 9, and country-specific genetic data laws (UK, DE, FR) restrict processing on infrastructure outside the data controller's direct control. Captive inference is compliant by design — no contractual interpretation required.
FDA AI/ML Guidance (2023)
AI-assisted drug discovery outputs referenced in regulatory submissions require documented, reproducible inference infrastructure. Static captive infrastructure guarantees identical hardware and software configuration across runs. Cloud auto-scaling groups cannot provide this guarantee — infrastructure changes dynamically.
IP Defensibility in Patent Disputes
Patent challenges require demonstrating that an AI-assisted discovery was made at a specific time with specific data and a specific model. Intics' immutable audit logs provide exactly this provenance — every query, every corpus snapshot, every model version, every output — timestamped and tamper-evident. Cloud black-box APIs cannot provide this.
GxP Namespace Isolation
R&D, Clinical, and Regulatory namespaces are independently isolated. R&D experimental runs cannot contaminate validated clinical data environments. Each namespace is independently validated to its specific compliance requirements — GxP for clinical, trade-secret controls for R&D.
"Every query your R&D team sends to a commercial AI API tells the vendor what you're working on. For competitive intelligence, that's your entire pipeline strategy. Captive inference makes those queries invisible — and gives you the audit trail to defend every AI-assisted discovery in a patent proceeding."
IP protection positioning for CSO
Who Delivers What
Cisco owns the bottom 3 layers — with a unique storage angle for R&D data lakes. Intics owns the top 2.
Cisco — Energy, Silicon, Iron
Energy
Multi-week R&D compute cycles require sustained, high-density power. Quarterly corpus re-analysis creates burst demand equivalent to imaging workloads. Cisco manages rack density, thermal design, and UPS architecture for uninterrupted research cycles — including colocation partnerships with pharma-grade SLAs.
Silicon
Xeon or EPYC CPUs (128-core) for the corpus preprocessing bottleneck — literature normalisation, patent parsing, entity pre-filtering, genomic sequence alignment. H100/A100 for deep analysis inference. NVIDIA Hopper as cost-optimised accelerator for sustained NLP monitoring workloads. Workload-driven, vendor-agnostic selection.
Iron
UCS X/C-Series as GPU hosts. Nexus 9000 for high-bandwidth east-west traffic — critical for terabyte-scale genomic data movement between preprocessing and inference tiers. High-capacity MDS storage for genomic data lakes and full-corpus snapshots. Intersight for lifecycle management and compliance posture monitoring.
Storage is the R&D differentiator. Genomic data lakes, full PubMed corpus snapshots, and proprietary compound libraries require high-capacity local storage. Cisco's MDS storage replaces the cloud storage bill entirely — and eliminates the $50K–$100K/yr in genomic data egress fees that accumulate when data moves to and from cloud for processing.
Intics — Intelligence, Agency
Intelligence (Model Serving)
Multi-model concurrent serving across 8B classification, 14B entity extraction, and 72B deep analysis models on the same infrastructure. Silicon-aware placement — classification tasks on NVIDIA Hopper (cost-optimised), complex mechanism analysis on H100. Burst scheduling for quarterly corpus re-analysis without disrupting real-time monitoring workloads.
The CPU/GPU optimisation that reduced 100 H100 pods to 48 without performance loss at the Fortune 25 customer applies directly to corpus-scale R&D — where preprocessing is a significant share of total pipeline time.
Agency (Discovery Copilot)
Multi-corpus pipeline orchestration across all 4 stages. Namespace isolation per therapeutic area — oncology, CNS, and cardiovascular teams share infrastructure but their queries, datasets, and model instances are fully isolated. Automated alerting (new patent matching therapeutic area → immediate notification to R&D lead). Queue priority management — urgent competitive queries get priority over batch corpus scanning.
Every query, every corpus snapshot, every model version, every output — timestamped and tamper-evident. Scientists get a self-service platform; Intics delivers the provenance trail that makes AI-assisted discovery defensible.
The same operational maturity that runs 124 GPU pods 24×7 at a Fortune 25 healthcare company — queue priority, failover, DR, prompt versioning, audit trails — is delivered to the R&D organisation on day one.
The Pitch
Direct to the pharma R&D leadership
"Your R&D organisation is paying $1M+ per year in commercial AI API fees to search literature and monitor patents — while simultaneously leaking its pipeline strategy through the tools it uses to protect it. We eliminate that spend entirely, replace it with owned infrastructure that breaks even in six months, and give your scientists a private intelligence platform where every query stays inside the firewall."
Key Numbers to Remember
$5.5–9M
3-Year Net Savings
Mo 6–8
Break-Even Point
$1M+/yr
Commercial API Spend Eliminated
$240K → $79K
Monthly: Cloud → Captive
35M+
PubMed Abstracts — Re-Analysed in 72 hrs
6–12 mo → hrs
Competitive Signal Detection Lag Eliminated
Zero
Query IP Leakage to Cloud Vendors
4 Stages
Ingestion → Knowledge Twin → Hypothesis → Copilot